! I’m your host today, Caroline Seymour.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by AADI Bioscience, we had the pleasure of speaking with Andrew J. Wagner, MD, PhD, about key long-term findings from the phase 2 AMPECT trial (NCT02494570) of nab-sirolimus (Fyarro) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Dr Wagner is the medical director of Ambulatory Oncology and a senior physician at Dana-Faber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

In our exclusive interview, Dr Wagner discussed current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.

That’s all we have for today! Thank you for listening to this episode of 

, sponsored by AADI Bioscience. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial. 

Andrew J. Wagner, MD, PhD

Articles

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa